- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01525992
A Community Pharmacy-based Program to Improve Management of Diabetes
A Community Pharmacy-based Intervention on Type 2 Diabetic Patients to Improve Medications Adherence and Disease Outcomes; a Randomized Controlled Trial.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Diabetes mellitus type 2 is a progressive metabolic disorder that leads to several morbidities and increased mortality and costs. Studies showed that strict control of blood glucose in diabetic patients reduces patients' risk of microvascular complications. Community pharmacies are a well-placed healthcare facility located at the heart of the community with convenient access to pharmacists as health care professionals. Some studies have shown effective interventions led by community and clinical pharmacist in developed countries. In developing countries, little evidence exists about feasibility of implementing community pharmacy-based services to promote medications adherence, self glucose monitoring and self-care in diabetic patients.
This study is a 2 arm randomized controlled trial. Eligible patients are referred to the community pharmacy from an endocrinologist's office. Of 135 type-2 diabetic patients who will be recruited in the study,68 will be randomly allocated to the intervention arm using telephone balanced blocked randomization method.
A community pharmacy-based program will provide training about medications, life style and self-care to the intervention arm. The control arm (67 patients) will receive usual care during the study period.
The primary outcome of this study is measured as change in hemoglobin A1C pre and post intervention. As the secondary outcome, medications adherence, diabetes self-care activity, body mass index and blood pressure are measured.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Tehran, Iran, Islamic Republic of
- Taleghani Community Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Type 2 diabetic patients using oral anti diabetic medications.
- Hemoglobin A1c > 7 within the previous month before recruitment
- Adequate literacy and ability to use the glucometer.
- Signing the informed consent
Exclusion Criteria:
- Patients requiring adjunct insulin therapy.
- Patients with concurrent heart failure (stage 4).
- Patients who fast in Ramadan.
- Patients receiving diabetes education in other programs.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Usual care
|
The baseline and 6-month follow-up visits to the community pharmacy will be required.
If the physician prefers more visits to his office during the study period, it will be granted.
The glucometer and a training session about diabetes self-care will be provide at the end of study for control group patients.
|
Experimental: Community Pharmacy-based Program
|
A trained pharmacist will counsel each patient based on his/her individual needs about medications, life style and self-care.
The pharmacist will use a checklist to document the type of education delivered to each patient.
A glucometer is provided for each patient in this arm to monitor blood glucose daily.
Three to six visits to the community pharmacy are set during the 6-months study period.
At each visit, medication related problems and self-care issues are discussed with the patient and the glucometer test strips are provided for the following month.
A telephone call will be made to each patient between visits to ensure adherence to drug therapy and resolve any problems .
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hemoglobin A1c
Time Frame: Change from baseline (at the point of recruiting) Hemoglobin A1c at 6 months.
|
Hemoglobin A1c is measured in all patients prior to participating in the study.
All patients will be required to take the test again at the end of the study (6 months) .
|
Change from baseline (at the point of recruiting) Hemoglobin A1c at 6 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Medication adherence
Time Frame: Change from baseline (at the point of recruiting) medication adherence at 6 months.
|
Medication adherence will be measured using "Morisky Medication Adherence Questionnaire" which will be translated into Farsi.The validity and reliability of the translated questionnaire will be investigated primarily.
|
Change from baseline (at the point of recruiting) medication adherence at 6 months.
|
Self-care activity
Time Frame: Change from baseline (at the point of recruiting) Self-care activity at 6 months.
|
Self-care activity will be measured using "Diabetes Self-care Activity Measure" questionnaire which will be translated into Farsi.
We will investigate the validity and reliability of the translated questionnaire.
|
Change from baseline (at the point of recruiting) Self-care activity at 6 months.
|
Body Mass Index
Time Frame: Change from baseline (at the point of recruiting) Body Mass Index at 6 months.
|
Weight (measured in kilograms) divided by square of height (measured in Meters).
|
Change from baseline (at the point of recruiting) Body Mass Index at 6 months.
|
Blood pressure
Time Frame: Change from baseline (at the point of recruiting) Blood pressure at 6 months.
|
Change from baseline (at the point of recruiting) Blood pressure at 6 months.
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Zahra Jahangard-Rafsanjani, PharmD, Tehran University Of Medical Sciences
- Study Chair: Kheirollah Gholami, M.Sc, PharmD, Tehran University Of Medical Sciences
- Principal Investigator: Arash Rashidian, MD, Ph.D, Tehran University Of Medical Sciences
- Principal Investigator: Navid Saadat, MD, Shahid Beheshti University of Medical Sciences
- Principal Investigator: Amir Sarayani, PharmD, MPH, Tehran University Of Medical Sciences
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 90-04-156-16161
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
AstraZenecaRecruiting
Clinical Trials on Community pharmacist-led diabetes education program
-
Dr. Chee Ping ChongHospital Raja Permaisuri BainunRecruitingAllergic Rhinitis | Pharmaceutical Care | Pharmaceutical ServicesMalaysia
-
London Health Sciences CentreUnknown
-
University of RochesterNational Cancer Institute (NCI)Recruiting
-
Medical University of South CarolinaNational Institutes of Health (NIH)CompletedCardiovascular Diseases | Diabetes Mellitus | Medication AdherenceUnited States
-
McGill UniversityUniversity of GhanaUnknownMalnutrition | Adolescent Behavior | Adolescent DevelopmentCanada, Ghana
-
Pemba Ministry of Health ZanzibarActive, not recruitingHealth Education | SchistosomiasisTanzania
-
Marmara UniversityCompleted
-
University of California, DavisRoche Pharma AGCompletedInfluenza, HumanUnited States
-
University of MichiganRecruiting
-
Norwegian University of Science and TechnologyKathmandu University School of Medical SciencesCompleted